Leerink Partnrs Has Bearish Estimate for Pfizer Q3 Earnings

Pfizer Inc. (NYSE:PFE) – Research analysts at Leerink Partnrs cut their Q3 2025 earnings per share (EPS) estimates for shares of Pfizer in a research report issued to clients and investors on Wednesday, February 5th. Leerink Partnrs analyst D. Risinger now forecasts that the biopharmaceutical company will post earnings of $1.10 per share for the quarter, down from their prior estimate of $1.11. The consensus estimate for Pfizer’s current full-year earnings is $2.96 per share. Leerink Partnrs also issued estimates for Pfizer’s FY2029 earnings at $2.36 EPS.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The business had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. During the same period in the previous year, the firm earned $0.10 EPS. The firm’s revenue was up 24.7% compared to the same quarter last year.

Several other analysts have also issued reports on PFE. Evercore ISI raised Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. Citigroup reduced their target price on Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. UBS Group reduced their target price on Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a report on Wednesday, January 8th. Sanford C. Bernstein assumed coverage on Pfizer in a research report on Thursday, October 17th. They set a “market perform” rating and a $32.00 price objective for the company. Finally, Truist Financial dropped their price objective on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Stock Performance

Shares of NYSE PFE opened at $25.83 on Friday. The firm has a market cap of $146.35 billion, a price-to-earnings ratio of 34.90, a P/E/G ratio of 0.66 and a beta of 0.64. Pfizer has a one year low of $24.48 and a one year high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The stock’s fifty day moving average price is $26.29 and its two-hundred day moving average price is $27.78.

Institutional Investors Weigh In On Pfizer

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Retirement Wealth Solutions LLC bought a new stake in Pfizer in the fourth quarter valued at $26,000. Gladius Capital Management LP increased its stake in Pfizer by 102.8% in the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 38,015 shares in the last quarter. Kohmann Bosshard Financial Services LLC bought a new stake in Pfizer in the fourth quarter valued at $28,000. Noble Wealth Management PBC bought a new stake in Pfizer in the fourth quarter valued at $31,000. Finally, Teachers Insurance & Annuity Association of America bought a new stake in Pfizer in the third quarter valued at $35,000. 68.36% of the stock is owned by institutional investors.

Pfizer Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be issued a $0.43 dividend. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. This represents a $1.72 annualized dividend and a yield of 6.66%. Pfizer’s payout ratio is presently 232.44%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.